Consolidative Camrelizumab Following Definitive Concurrent Chemoradiation Therapy With Involved-Field Irradiation in Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial.

Int J Radiat Oncol Biol PhysApr 22, 2026 (epub)
Clinical ResearchOncology (Medical)Gastroenterology

Yunjie Cheng, Jianing Wang, Xiaoyan Lv et al.

✦ AI-curated · Sources linked

In 30 seconds

This single-arm phase 2 trial evaluated the efficacy of camrelizumab consolidation therapy in 32 patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) following definitive concurrent chemoradiation therapy (dCCRT). The study found a disease control rate of 59.4% and 1-year progression-free survival (PFS) rate of 81.3%.

Key findings

  • The disease control rate was 59.4% (19 of 32 patients).
  • 1-year progression-free survival (PFS) rate was 81.3%.
  • 1-year overall survival (OS) rate was 96.9%.
  • Most adverse events were grade 1 or 2, with anemia occurring in 68.8% of patients.

Why it matters

The study highlights the potential role of consolidation immunotherapy in improving outcomes for patients with unresectable locally advanced ESCC, a population at high risk for recurrence after standard treatment.

Source

PubMed · PMID 42031221

Published in Int J Radiat Oncol Biol Phys. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.